QRISK3 cardiovascular risk calculator
Authored by Patient infomatics teamOriginally published 8 Feb 2026
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
Medical Professionals
Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our health articles more useful.
QRISK3 is a validated cardiovascular risk prediction tool used to estimate a patient’s 10-year risk of developing cardiovascular disease. It is widely used in UK primary care to support decisions about risk reduction, including lifestyle advice and statin therapy.
The calculator builds on earlier QRISK models by incorporating a broader range of clinical and demographic risk factors, improving risk estimation for groups previously under-represented.
Clinical context and use
QRISK3 is used in adults aged 25–84 years who do not already have established cardiovascular disease.
It estimates the risk of a first cardiovascular event, including myocardial infarction, angina, stroke, or transient ischaemic attack, over the next 10 years.
The score is commonly used during NHS health checks and routine cardiovascular risk assessment in general practice.
The output supports shared decision-making around prevention strategies and should be recalculated periodically as risk factors change.
Factors included in QRISK3
QRISK3 incorporates traditional cardiovascular risk factors alongside additional clinical variables. These include:
Age.
Sex.
Ethnicity.
Smoking status.
Blood pressure.
Cholesterol ratio.
Family history of premature cardiovascular disease.
It also includes conditions and factors not present in earlier models, such as:
Corticosteroid use.
,Severe mental illness.
Atypical antipsychotic use.
Systemic inflammatory conditions.
By accounting for these factors, QRISK3 provides a more personalised estimate of cardiovascular risk.
Understanding the result
The result is expressed as a percentage, representing the estimated chance of experiencing a cardiovascular event in the next 10 years.
In UK practice, a 10-year risk of 10 percent or higher is commonly used as a threshold for considering statin therapy, alongside lifestyle modification and individual patient preference.
Risk should always be interpreted in context, taking into account patient values, comorbidities, and potential benefits and harms of treatment.
Role in prevention and treatment decisions
QRISK3 supports a preventive approach to cardiovascular disease by identifying patients who may benefit from early intervention.
It helps guide discussions about smoking cessation, diet, physical activity, weight management, and blood pressure control. Where appropriate, it also informs decisions about lipid-lowering therapy.
The calculator does not mandate treatment but provides an evidence-based estimate to support informed discussion.
Evidence base
QRISK3 was developed using large UK primary care datasets and has been externally validated in diverse populations.
It has demonstrated improved calibration and discrimination compared with earlier QRISK models, particularly in groups with conditions associated with elevated cardiovascular risk.
QRISK3 is referenced in NICE guidance for cardiovascular disease risk assessment and lipid modification.
Limitations and clinical judgement
QRISK3 estimates population-level risk and cannot predict individual outcomes with certainty.
It may underestimate or overestimate risk in some individuals, particularly those at the extremes of age or with uncommon risk profiles. It is not intended for use in patients with established cardiovascular disease, where secondary prevention guidance applies.
Clinical judgement remains essential, especially where calculated risk is close to treatment thresholds.
Practical use in consultation
Using QRISK3 provides a structured way to discuss cardiovascular risk and prevention. Visualising risk can help patients understand the potential benefits of lifestyle change or medication.
Recording the score supports documentation, audit, and continuity of care. Risk should be reviewed periodically, particularly if there are changes in health status or treatment.
Patient picks for Cardiovascular disease

Professional
Cardiovascular risk assessment
Cardiovascular risk assessment purpose Cardiovascular disease: risk assessment and reduction, including lipid modification; NICE Clinical Guideline (July 2014 -last updated May 2023) Replaced by NG238 66598 : NICE CG181 Cardiovascular disease: risk assessment and reductio... Full formal risk assessment Use the QRISK3 tool QRISK3 cardiovascular.
by Dr Colin Tidy, MRCGP

Professional
Prevention of cardiovascular disease
The revised Joint British Societies' (JBS 3) guidelines on prevention of cardiovascular disease (CVD) in clinical practice recommend that CVD prevention should focus equally on the following three groups of patients who are at high risk of CVD: Report of the Joint British Societies for th... In the UK the QRISK score is recommended for estimating.
by Dr Hayley Willacy, FRCGP

Professional
Cardiovascular history and examination
Family cardiac history Ask about hypertension, coronary heart disease, stroke, diabetes, hyperlipidaemia, congenital heart disease and any early deaths (before the age of 60) ... Lifestyle Include ensuring appropriate prevention of cardiovascular disease Prevention of cardiovascular disease (including calculation of cardiovascular risk.
by Dr Colin Tidy, MRCGP

Professional
CHA₂DS₂-VASc score
The CHA₂DS₂-VASc score is a clinical risk stratification tool used to estimate the risk of stroke and systemic embolism in patients with atrial fibrillation (AF). It is widely used to guide decisions about oral anticoagulation. The score refines earlier risk models by including additional vascular and demographic risk factors and is recommended in.
by Patient infomatics team

Professional
Pulmonary embolism
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism; NICE Technology Appraisal Guidance, June 2013 30958 : NICE TA287 Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism Risk factors Konstantinides SV, Meyer G, Becattini C, et al; 2019 ESC Guidelines for the diagnosis.
by Dr Doug McKechnie, MRCGP

Professional
Coronary artery calcium score
The coronary artery calcium score (CACS) is considered one such tool and i... The presence of calcium in coronary arteries is almost always indicative of atherosclerotic plaque (but bears no relationship to plaque stability or instability). 2021 European Guidelines on cardiovascular disease prevention in clinical practice; European Society of.
by Dr Colin Tidy, MRCGP
Exclusive updates for healthcare professionals
Stay informed with the latest clinical updates, professional insights, and evidence-based guidance. The Patient Pro newsletter curates essential content for healthcare professionals—delivered straight to your inbox.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.
More in cardiovascular disease
- Ambulatory blood pressure monitoring
- Aneurysms and dissection of arteries
- Antiplatelet drugs
- Aortic dissection
- Cardiovascular history and examination
- Diabetes and hypertension
- Exercise tolerance testing
- Fluid overload
- Flying with medical conditions
- Heart failure management
- Heart murmurs in children
- Infective endocarditis
- Microvascular angina
- Pulmonary embolism
- Pulse examination
- Sarcoidosis
- Tricuspid valve disease
- Ventricular septal defect
- Wells’ criteria for deep vein thrombosis (DVT)
- Wolff-Parkinson-White syndrome


